During the last three months, 4 analysts shared their evaluations of bluebird bio (NASDAQ:BLUE), revealing diverse outlooks from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for bluebird bio, presenting an average target of $2.92, a high estimate of $6.00, and a low estimate of $1.02. Highlighting a 5.81% decrease, the current average has fallen from the previous average price target of $3.10.

Decoding Analyst Ratings: A Detailed Look

In examining recent analyst actions, we...